Cargando…
Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753914/ https://www.ncbi.nlm.nih.gov/pubmed/33363365 http://dx.doi.org/10.2147/COPD.S274354 |
_version_ | 1783626085967069184 |
---|---|
author | Lim, Jeong Uk Kang, Hye Seon Yeo, Chang Dong Kim, Ju Sang Park, Chan Kwon Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak |
author_facet | Lim, Jeong Uk Kang, Hye Seon Yeo, Chang Dong Kim, Ju Sang Park, Chan Kwon Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak |
author_sort | Lim, Jeong Uk |
collection | PubMed |
description | BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in NSCLC. METHODS: Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 in seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test results and cutoffs for NLR or PLR. RESULTS: A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non-COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P = 0.019). Median survival was significantly different between high/low PLR groups (P < 0.001), between high/low NLR groups (P = 0.001), and between high/low c-reactive protein (CRP) groups (P < 0.001). PLR, NLR and CRP showed significant correlations with each other. PLR showed a significant negative linear correlation with FVC (absolute) (r = −0.149, P = 0.015), FVC (%) (r = −0.192, P = 0.002), DLCO (absolute) (r = −0.271, P < 0.001), DLCO (%) (r = −0.139, P = 0.032), and NLR (r = 0.718, P < 0.001). In the multivariate analysis, the high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175–3.633), P = 0.012) compared with the low-PLR non-COPD group. However, COPD-NLR subtype was not an independent predictor for OS. CONCLUSION: A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC. |
format | Online Article Text |
id | pubmed-7753914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77539142020-12-23 Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study Lim, Jeong Uk Kang, Hye Seon Yeo, Chang Dong Kim, Ju Sang Park, Chan Kwon Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in NSCLC. METHODS: Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 in seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test results and cutoffs for NLR or PLR. RESULTS: A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non-COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P = 0.019). Median survival was significantly different between high/low PLR groups (P < 0.001), between high/low NLR groups (P = 0.001), and between high/low c-reactive protein (CRP) groups (P < 0.001). PLR, NLR and CRP showed significant correlations with each other. PLR showed a significant negative linear correlation with FVC (absolute) (r = −0.149, P = 0.015), FVC (%) (r = −0.192, P = 0.002), DLCO (absolute) (r = −0.271, P < 0.001), DLCO (%) (r = −0.139, P = 0.032), and NLR (r = 0.718, P < 0.001). In the multivariate analysis, the high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175–3.633), P = 0.012) compared with the low-PLR non-COPD group. However, COPD-NLR subtype was not an independent predictor for OS. CONCLUSION: A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC. Dove 2020-12-14 /pmc/articles/PMC7753914/ /pubmed/33363365 http://dx.doi.org/10.2147/COPD.S274354 Text en © 2020 Lim et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lim, Jeong Uk Kang, Hye Seon Yeo, Chang Dong Kim, Ju Sang Park, Chan Kwon Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title | Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title_full | Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title_fullStr | Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title_full_unstemmed | Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title_short | Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study |
title_sort | impact of combined chronic obstructive pulmonary disease status and systemic inflammation on outcome of advanced nsclc: multicenter retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753914/ https://www.ncbi.nlm.nih.gov/pubmed/33363365 http://dx.doi.org/10.2147/COPD.S274354 |
work_keys_str_mv | AT limjeonguk impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT kanghyeseon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT yeochangdong impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT kimjusang impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT parkchankwon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT kimyonghyun impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT kimjinwoo impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT kimseungjoon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy AT leesanghaak impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy |